fungal infections
RealSeq Biosciences Raises $1.5M in Oversubscribed Seed Financing Round
The company will use the funding to validate its RiboMarker platform and further develop its laboratory-developed test for Valley Fever.
Rapid Pathogen ID/AST Market Begins to Recover Post-COVID as Drug-Resistant Infections Spike
Premium
Although bacterial and fungal drug resistance rates increased during the pandemic, a heavy focus on COVID testing has slowed adoption of novel ID/AST technologies.
Immy Wins $1.5M NIH Contract for Point-of-Care Talaromycosis Test
Talaromycosis is an infection caused by airborne inhalation of the fungus Talaromyces marneffei and is endemic in Southeast Asia.
Pathonostics Gets CE Mark for Next-Gen Test for Fungal Skin Infections
The multiplex PCR test can detect and distinguish more than 15 fungal pathogens that cause dermatophytosis.
BGI Bloodstream Pathogen Nucleic Acid Detection Kit Gets CE Mark
The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, is designed to construct a metagenomic sequencing library directly from clinical samples.
Jul 29, 2019
Jan 25, 2019
Jul 30, 2018
GenMark Diagnostics Q2 Revenues Rise 20 Percent
Dec 6, 2017
FDA Clears DxNA's Valley Fever Molecular Test
Dec 6, 2017
Oct 18, 2017
Jul 18, 2017
T2 Biosystems Receives CE Mark for Bacterial Panel
Feb 28, 2017
Nov 3, 2016
GenMark Diagnostics Q3 Revenues Up 28 Percent
Sep 20, 2016
Aug 26, 2016